Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EXEL Exelixis	$43.67 +1.3%	$40.92	$21.82 ▼ $49.62	$11.91B	0.28	2.45 million shs	3.52 million shs
PFE Pfizer	$24.20 -0.2%	$23.42	$20.92 ▼ $31.54	$137.56B	0.57	41.34 million shs	39.50 million shs
REGN Regeneron Pharmaceuticals	$521.00	$555.02	$476.49 ▼ $1,211.20	$56.25B	0.31	898,982 shs	1.61 million shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EXEL Exelixis	-1.01%	+5.77%	0.00%	+17.41%	+92.54%
PFE Pfizer	+0.06%	+1.80%	+2.94%	-3.56%	-11.36%
REGN Regeneron Pharmaceuticals	+0.14%	+1.44%	-13.64%	-18.26%	-51.27%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
EXEL Exelixis	4.6355 of 5 stars	2.3	1.0	0.0	4.3	2.7	2.5	4.4
PFE Pfizer	4.866 of 5 stars	2.3	3.0	4.2	4.3	2.9	1.7	3.1
REGN Regeneron Pharmaceuticals	4.93 of 5 stars	4.4	5.0	1.7	2.3	2.7	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EXEL Exelixis	2.52	Moderate Buy	$43.22	-1.03% Downside
PFE Pfizer	2.53	Moderate Buy	$29.17	20.54% Upside
REGN Regeneron Pharmaceuticals	2.83	Moderate Buy	$813.57	56.15% Upside

Current Analyst Ratings Breakdown

Latest EXEL, PFE, and REGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/24/2025	EXEL Exelixis	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$50.00
6/24/2025	EXEL Exelixis	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight	$29.00 ➝ $60.00
6/23/2025	EXEL Exelixis	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
6/23/2025	EXEL Exelixis	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$43.00 ➝ $55.00
6/23/2025	EXEL Exelixis	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$47.00 ➝ $50.00
6/12/2025	EXEL Exelixis	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00 ➝ $47.00
6/9/2025	REGN Regeneron Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$950.00 ➝ $800.00
6/5/2025	EXEL Exelixis	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$45.00 ➝ $46.00
6/5/2025	REGN Regeneron Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$633.00 ➝ $560.00
6/2/2025	REGN Regeneron Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$700.00 ➝ $650.00
6/2/2025	REGN Regeneron Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$800.00 ➝ $600.00

(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EXEL Exelixis	$2.17B	5.49	$1.93 per share	22.60	$7.86 per share	5.56
PFE Pfizer	$63.63B	2.16	$4.35 per share	5.56	$15.62 per share	1.55
REGN Regeneron Pharmaceuticals	$14.20B	3.96	$45.74 per share	11.39	$268.50 per share	1.94

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EXEL Exelixis	$521.27M	$2.20	19.85	17.13	0.87	27.99%	28.81%	21.94%	8/5/2025 (Estimated)
PFE Pfizer	$8.03B	$1.38	17.53	7.99	0.88	12.62%	20.33%	8.53%	8/5/2025 (Estimated)
REGN Regeneron Pharmaceuticals	$4.41B	$39.28	13.26	13.70	1.91	31.94%	15.27%	11.93%	7/30/2025 (Estimated)

Latest EXEL, PFE, and REGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
4/29/2025	Q1 2025	PFE Pfizer	$0.67	$0.92	+$0.25	$0.52	$14.43 billion	$13.72 billion
4/29/2025	Q1 2025	REGN Regeneron Pharmaceuticals	$8.83	$8.22	-$0.61	$7.27	$3.40 billion	$3.03 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EXEL Exelixis	N/A	N/A	N/A	N/A	N/A
PFE Pfizer	$1.72	7.11%	N/A	124.64%	16 Years
REGN Regeneron Pharmaceuticals	$3.52	0.68%	N/A	8.96%	N/A

Latest EXEL, PFE, and REGN Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/25/2025	PFE Pfizer	quarterly	$0.43	7.08%	7/25/2025	7/25/2025	9/2/2025
4/23/2025	PFE Pfizer	quarterly	$0.43	7.69%	5/9/2025	5/9/2025	6/13/2025
5/20/2025	REGN Regeneron Pharmaceuticals	quarterly	$0.88	0.6%	5/20/2025	5/20/2025	6/6/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EXEL Exelixis	N/A	3.50	3.44
PFE Pfizer	0.64	1.26	0.96
REGN Regeneron Pharmaceuticals	0.09	4.93	4.03

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EXEL Exelixis	85.27%
PFE Pfizer	68.36%
REGN Regeneron Pharmaceuticals	83.31%

Insider Ownership

Company	Insider Ownership
EXEL Exelixis	2.82%
PFE Pfizer	0.06%
REGN Regeneron Pharmaceuticals	7.02%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EXEL Exelixis	1,147	272.71 million	265.02 million	Optionable
PFE Pfizer	81,000	5.69 billion	5.68 billion	Optionable
REGN Regeneron Pharmaceuticals	15,106	107.96 million	100.39 million	Optionable

EXEL, PFE, and REGN Headlines

Recent News About These Companies

Regeneron’s Phase 3 Trial: A New Hope for Follicular Lymphoma Treatment

June 27 at 12:56 PM | tipranks.com

Regeneron’s Promising Cancer Study: A Closer Look at REGN7075 and Cemiplimab

June 27 at 12:56 PM | tipranks.com

Hunter Perkins Capital Management LLC Acquires Shares of 8,482 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

June 27 at 7:47 AM | marketbeat.com

Illinois Municipal Retirement Fund Acquires 2,774 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

June 27 at 7:45 AM | marketbeat.com

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Loring Wolcott & Coolidge Fiduciary Advisors LLP MA

June 27 at 6:54 AM | marketbeat.com

Robeco Institutional Asset Management B.V. Sells 16,813 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

June 27 at 5:01 AM | marketbeat.com

Regeneron Pharmaceuticals Schedules Second Quarter 2025 Financial Results Announcement and Conference Call

June 26 at 4:20 PM | quiverquant.comQ

Regeneron to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2025

June 26 at 4:16 PM | globenewswire.com

SA analyst upgrades/downgrades: AAPL, FCX, REGN, AMBA

June 26 at 1:35 PM | msn.com

Regeneron’s New NSCLC Study: Potential Game-Changer in Cancer Treatment?

June 26 at 12:40 PM | tipranks.com

Regeneron’s Innovative Approach: Linvoseltamab in Multiple Myeloma Study

June 26 at 12:40 PM | tipranks.com

Regeneron’s Gene-Silencing Study for MASH: A Potential Market Game-Changer

June 26 at 12:40 PM | tipranks.com

Regeneron’s Linvoseltamab Trial: A Potential Game-Changer in Multiple Myeloma Treatment

June 26 at 12:40 PM | tipranks.com

Global Assets Advisory LLC Makes New $443,000 Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

June 26 at 4:55 AM | marketbeat.com

Regeneron Launches $200 Million Donation Matching Program to Support Vision Care

June 25 at 8:27 PM | finance.yahoo.com

Regeneron’s Heart Failure Study: A Potential Game-Changer in Cardiovascular Treatment

June 25 at 12:38 PM | tipranks.com

Regeneron Pharmaceuticals Stock May Be Worth Buying Again - Rating Upgrade

June 25 at 9:28 AM | seekingalpha.com

Regeneron: Negative Scenario Is Being Realized (Rating Downgrade)

June 25 at 8:16 AM | seekingalpha.com

Adams Diversified Equity Fund Inc. Has $12.49 Million Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

June 25 at 6:54 AM | marketbeat.com

Asset Management One Co. Ltd. Purchases 2,358 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

June 25 at 4:41 AM | marketbeat.com

Envestnet Portfolio Solutions Inc. Sells 913 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

June 25 at 3:32 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

EXEL, PFE, and REGN Company Descriptions

Exelixis NASDAQ:EXEL

$43.67 +0.58 (+1.35%)

Closing price 04:00 PM Eastern

Extended Trading

$43.74 +0.07 (+0.17%)

As of 07:50 PM Eastern

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Pfizer NYSE:PFE

$24.20 -0.04 (-0.18%)

Closing price 03:59 PM Eastern

Extended Trading

$24.18 -0.02 (-0.07%)

As of 08:00 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Regeneron Pharmaceuticals NASDAQ:REGN

$521.00 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$524.00 +3.00 (+0.58%)

As of 07:50 PM Eastern

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time